Coherus Oncology (CHRS) Cash from Operations Growth (1y) (2014 - 2026)
Coherus Oncology (CHRS) Cash from Operations Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | - |
| 4 | BeOne Medicines | 470.64 Bn | 465.84 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 122.91 Bn | 115.67 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.77 Bn | 62.77 Bn | - | - |
| 8 | Argenx Se | 56.21 Bn | 51.02 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.60 Bn | 37.60 Bn | - | - |
| 10 | Coherus Oncology | 197.78 Mn | 30.73 Mn | 8.50 Mn | -124.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -124.14% |
| Dec 31, 2025 | -168.92% |
| Sep 30, 2025 | 25.28% |
| Jun 30, 2025 | -178.07% |
| Mar 31, 2025 | 44.78% |
| Dec 31, 2024 | 321.13% |
| Sep 30, 2024 | -14.21% |
| Jun 30, 2024 | 253.50% |
| Mar 31, 2024 | 31.96% |
| Dec 31, 2023 | 87.06% |
| Sep 30, 2023 | -46.40% |
| Jun 30, 2023 | 22.23% |
| Mar 31, 2023 | -27.18% |
| Dec 31, 2022 | -91.03% |
| Sep 30, 2022 | -370.51% |
| Jun 30, 2022 | -26,515.43% |
| Mar 31, 2022 | -4,053.55% |
| Dec 31, 2021 | -257.96% |
| Sep 30, 2021 | -71.05% |
| Jun 30, 2021 | -100.31% |